GlaxoSmithKline (GSK) confirmed on 22nd July that it had contracts to supply 195 million doses of its pandemic (H1N1) 2009 adjuvanted influenza vaccine. It also had a variety of agreements in place with the US Government to supply pandemic products worth $250 million.
GSK also said that, since then, it has signed nine more government contracts for a further 96 million doses of the vaccine. This now brings the total number of doses ordered for GSK’s adjuvanted vaccine to 291 million.
The first supplies of the vaccine will be available to governments from September onwards, with shipments expected in the second half of 2009 and early 2010. The exact pace of delivery will be dependent on capacity and the yield of the influenza strain, said the company.